Clinical Trials | March 03, 2026
AbbVie’s Risankizumab shows strong results in hard-to-treat Crohn’s disease patients
This study evaluated a difficult-to-treat Crohn's disease patient population
This study evaluated a difficult-to-treat Crohn's disease patient population
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
The positive outcome clears the way for Glenmark to resume commercial manufacturing at the site
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Amgen has invested over $40 billion in manufacturing and research and development in US since 2017
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.
Subscribe To Our Newsletter & Stay Updated
